Search results
Added:
5 months ago
Source:
Radcliffe Cardiology
Natriuretic peptides are key biomarkers used to risk-stratify patients with heart failure (HF), but current guideline thresholds do not typically account for body mass index (BMI).¹ A new pooled analysis suggests that these fixed thresholds may underestimate risk in patients with HF and higher BMI, questioning the one-size-fits-all approach.²This study was a participant-level pooled analysis of…
View more
Added:
4 months ago
Source:
Radcliffe CVRM
A new pooled analysis suggests that measures of abdominal adiposity, such as waist-to-height ratio, are better predictors of clinical outcomes than body mass index (BMI) alone in patients with heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Obesity is highly prevalent in this patient population and is linked to an increased risk of mortality and disability.This…
View more
Added:
3 months ago
Source:
Radcliffe Cardiology
A new study published in JACC has evaluated the prevalence and prognostic significance of secondary tricuspid regurgitation (STR) across the spectrum of heart failure with preserved ejection fraction (HFpEF), finding that its presence is strongly associated with pulmonary vascular disease (PVD) and that different mechanisms of STR carry distinct prognoses.¹˒²This observational study analysed data…
View more
Added:
1 year ago
Source:
Radcliffe Cardiology
AUTHOR: Jordan Rance; Special Editor: Greg GuilloryA new analysis sheds light on the timing of protection offered by SGLT2 inhibitors. Researchers conducted a cross-trial analysis using individual participant data from four large-scale randomized clinical trials: CANVAS (type 2 diabetes with high atherosclerotic risk, NCT01032629), CREDENCE (diabetic kidney disease, NCT02065791), DAPA-HF (heart…
View more
Added:
3 weeks ago
Source:
Transcatheter Academy
A new study suggests that for elderly patients with atrial functional mitral regurgitation (AFMR), transcatheter edge-to-edge repair (TEER) is associated with a lower risk of mortality and heart failure hospitalisation compared with conventional medical therapy. The findings come from a propensity score-based comparison of two large Japanese registries, OCEAN-Mitral and REVEAL-AFMR…
View more
Added:
8 months ago
Source:
Radcliffe CVRM
A secondary analysis of the SUMMIT trial has found that the benefits of tirzepatide on reducing the risk of cardiovascular death or worsening heart failure (HF) are consistent across all levels of obesity in patients with heart failure with preserved ejection fraction (HFpEF).¹ However, patients with a higher baseline body mass index (BMI) experienced greater improvements in exercise capacity and…
View more
Added:
1 year ago
Source:
THT
THT conference has released its four late-breaking trial sessions for 2025.The fourth annual Technology and Heart Failure Therapeutics conference is set to take place from the 11th to 13th February at Omni Boston Hotel at the Seaport in Boston. Access the full programme here.Late Breaking Clinical Science Session ITuesday 11th February, 09:30 – 10:45am ESTRobotic Surgical Technique for Performing…
View more
Added:
4 months ago
Source:
Radcliffe Cardiology
Communicating long-term cardiovascular disease (CVD) risk to younger adults can be challenging, but new research offers a tool to frame risk relative to an individual's peers. Investigators have developed population-based, age- and sex-specific percentiles for 30-year risk of CVD, atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF) using the PREVENT (Predicting Risk of CVD…
View more
Added:
4 months ago
Source:
Radcliffe Cardiology
A new post hoc analysis of the SUMMIT trial suggests the HFpEF-ABA score is a more effective and inclusive enrichment tool than natriuretic peptide (NP) levels for clinical trials in patients with obesity-related heart failure with preserved ejection fraction (HFpEF).¹ The findings indicate the score, which is based on age, body mass index (BMI), and history of atrial fibrillation (AF), can…
View more
Added:
2 years ago
Source:
Radcliffe Cardiology
AUTHOR: Greg GuilloryTwo late-breaking clinical trials addressing cardiovascular outcomes in patients with diabetes were presented this week at the American College of Cardiology meeting in Atlanta, USA. One of these trials looked at the effects of the hyperactivation of the polyol pathway on diabetic cardiomyopathy (DbCM) and the other the effects of chelation therapy in patients with diabetes…
View more